Immunology and inflammation

News

Astellas pays $285m for Audax cancer drug, and other deals

Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.

News

UK Biobank partners with industry on 'most detailed' immune ...

The UK Biobank has teamed up with industry partners to create "the world’s most detailed, large-scale picture of the human immune system."

News

A female palm containing a Rhapsido tablet

Rhapsido is first drug cleared for chronic hives disorder SD

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.

News

Novartis taps China's Abogen for autoimmunity TCE

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

News

Sanofi forges new $8bn pact with Regeneron

Sanofi's long-running R&D alliance with Regeneron has gone up a gear with a new deal – including a $1bn upfront payment – that spans four new drugs.

News

Apogee buy delivers eczema trial win for AbbVie

AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.

Astellas pays $285m for Audax cancer drug, and other deals

UK Biobank partners with industry on 'most detailed' immune ...

Rhapsido is first drug cleared for chronic hives disorder SD

Novartis taps China's Abogen for autoimmunity TCE

Sanofi forges new $8bn pact with Regeneron

Apogee buy delivers eczema trial win for AbbVie

Cure HHT wins inaugural Prix Galien Patient First Award

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks